Prostaglandin E2 (PGE2) autoamplifies its production through EP1 subtype of PGE receptor in mouse osteoblastic MC3T3-E1 cells.
Prostaglandin E2 (PGE2) is known to autoamplify its production in the osteoblasts through the induction of prostaglandin G/H synthase-2 (PGHS-2), which is the inducible form of the rate-limiting enzyme in PG synthesis, PGHS. To elucidate the cellular mechanism mediating this process, we have employed the PGE2 analogs, which are specific agonists for four subtypes of PGE receptor, and studied the potency of these analogs to induce PGHS-2 mRNA in mouse osteoblastic MC3T3-E1 cells. The induction was mainly observed by 17-phenyl-omega-trinor PGE2 (EP1 agonist) and sulprostone (EP3/EP1 agonist), but not by butaprost (EP2 agonist) or 11-deoxy PGE1 (EP4/EP2 agonist). Since EP3 subtype was undetectable in MC3T3-E1 cells, these data indicate that PGHS-2 mRNA induction is mediated through EP1 subtype of PGE receptor in MC3T3-E1 cells. PGE2 production determined by radioimmunoassay was also increased by 17-phenyl-omega-trinor PGE2 and sulprostone. The autoamplification of PGE2 production is considered to be important in elongating the otherwise short-lived PGE2 action in certain physiological conditions such as mechanical stress and fracture healing, as well as the pathological inflammatory bone loss. The observations in the present study provide us with the better understanding of these processes.
Suda
M
M
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Sakyo, Kyoto 606-01 Japan.
Tanaka
K
K
Yasoda
A
A
Natsui
K
K
Sakuma
Y
Y
Tanaka
I
I
Ushikubi
F
F
Narumiya
S
S
Nakao
K
K
D016475:3T3 Cells; D000020:Abortifacient Agents, Nonsteroidal / Q000494:pharmacology; D000527:Alprostadil / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D051546:Cyclooxygenase 2; D015232:Dinoprostone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000235:genetics / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000494:pharmacology; D015544:Inositol 1,4,5-Trisphosphate / Q000378:metabolism; D007527:Isoenzymes / Q000187:drug effects / Q000235:genetics; D051379:Mice; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D010120:Oxytocics / Q000008:administration & dosage / Q000494:pharmacology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects / Q000235:genetics; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D018078:Receptors, Prostaglandin E / Q000145:classification / Q000187:drug effects*
D000020:Abortifacient Agents, Nonsteroidal; D005343:Fibrinolytic Agents; D007527:Isoenzymes; D010120:Oxytocics; D011459:Prostaglandins E, Synthetic; D012333:RNA, Messenger; D018078:Receptors, Prostaglandin E; C016767:sulprostone; D015544:Inositol 1,4,5-Trisphosphate; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D000527:Alprostadil; C048491:butaprost; D015232:Dinoprostone